|
The world anxiously awaits a vaccine against the SARS-CoV-2 virus, which has caused the COVID-19 pandemic. Pharmaceutical companies are moving at an unprecedented rate with at least 120 projects launched worldwide, involving gene-based vaccines, inactivated vaccines, or live vaccines with viral vectors, to name a few. One promising project is triggering stronger immune responses in recipients than those seen in people naturally recovering from an infection of COVID-19.
|